View by Specialty

Trending

Anthony A. Romeo
November 15, 2024
4 min read
Save

Capitalism is the path to value-based care

Lymphoma News

SPONSORED CONTENT
Save
SPONSORED CONTENT
April 01, 2022
3 min read
Save

Patient-reported outcomes linked to nonfatal self-injury after cancer diagnosis

Patient-reported outcomes linked to nonfatal self-injury after cancer diagnosis

Self-reported signs of distress and an increasing total Edmonton Symptom Assessment System score within 180 days of cancer diagnosis appeared associated with higher odds of nonfatal, self-inflicted injury, study results showed.

SPONSORED CONTENT
March 24, 2022
2 min read
Save

MD Anderson launches James P. Allison immunotherapy institute to ‘enable cures’ for cancer

MD Anderson launches James P. Allison immunotherapy institute to ‘enable cures’ for cancer

The University of Texas MD Anderson Cancer announced Thursday the launch of the James P. Allison Institute, a research and innovation hub that integrates immunobiology across disciplines to accelerate discoveries toward cancer cures.

Trending

Anthony A. Romeo
November 15, 2024
4 min read
Save

Capitalism is the path to value-based care

SPONSORED CONTENT
March 23, 2022
4 min read
Save

Investigational therapy for B-cell malignancies offers three targets in one CAR T cell

Investigational therapy for B-cell malignancies offers three targets in one CAR T cell

B-cell activating factor is a ligand protein, which makes it uniquely suited as a therapeutic option for the newly emerging class of multitargeted chimeric antigen receptor T-cell therapies.

SPONSORED CONTENT
March 21, 2022
3 min read
Save

Early intrathecal therapy shows promise for managing neurotoxicity related to CAR-T

Early intrathecal therapy shows promise for managing neurotoxicity related to CAR-T

Early intrathecal therapy effectively resolved symptoms related to high-grade neurotoxicity among patients who received chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma, according to a research letter in JAMA Oncology.

SPONSORED CONTENT
March 18, 2022
3 min read
Save

ASCO members urged to help support cancer care in Ukraine, host countries

ASCO members urged to help support cancer care in Ukraine, host countries

As important as the care of Ukrainian citizens with cancer is to clinicians in that country, this priority has been overshadowed by more immediate concerns.

SPONSORED CONTENT
March 17, 2022
2 min read
Save

Age at diagnosis and cancer subtype may affect risk for CV death among cancer survivors

Age at diagnosis and cancer subtype may affect risk for CV death among cancer survivors

Among survivors of nine common cancers, risk for CV death overtook cancer mortality for most cancer subtypes among patients aged at least 80 years, researchers reported.

SPONSORED CONTENT
March 17, 2022
4 min read
Save

‘Like’ it or not: The dos and don’ts of social media for oncologists

‘Like’ it or not: The dos and don’ts of social media for oncologists

Just as physicians became accustomed to wearing pagers 40 years ago or being tied to smartphones 2 decades ago, many have become active on social media as it entered their practices.

SPONSORED CONTENT
March 17, 2022
11 min read
Save

In age of misinformation, cancer care community seeks new ways to improve communication

In age of misinformation, cancer care community seeks new ways to improve communication

An important component of cancer care is communication with patients and caregivers about their disease.

SPONSORED CONTENT
March 15, 2022
3 min read
Save

New cancer diagnosis associated with risk for fatal, nonfatal cardiovascular events

New cancer diagnosis associated with risk for fatal, nonfatal cardiovascular events

New cancer diagnosis appeared associated with increased risk for cardiovascular death, as well as incident heart failure, stroke or pulmonary embolism, according to a retrospective cohort study published in JACC: CardioOncology.

SPONSORED CONTENT
March 15, 2022
2 min read
Save

Only 14% of new cancer drug approvals displace existing standards of care

Only 14% of new cancer drug approvals displace existing standards of care

Most cancer drug approvals between 2016 and 2021 applied to second-, third- or later-line treatment settings and did not displace current standard-of-care therapies, according to a study published in JAMA Network Open.

View more